Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.

Advertisement

Related Content

Supreme Court’s Drug Patent Ruling Could Expand Use Of Expert Testimony
Supreme Court’s Copaxone Ruling Could Increase Expert Witness Testimony
Supreme Court Struggles Over What Constitutes A ‘Fact’ In Copaxone Case
Copaxone Supreme Court Case Could Cut Relitigation Of Patent Claims
Supreme Court Copaxone Case May Weaken Federal Circuit Review Of Patent Claims
Fourth Time’s The Charm? Teva Cites Colloids in Latest Attempt to Convince FDA to Require Clinical Trials for Generic Copaxone
Teva’s New CEO Levin Urges “Fiscal, Strategic Discipline,” Reduces 2012 Guidance
Lipitor Goes Generic, But First-Filer Ranbaxy’s Approval Leaves Plenty Of Questions In Its Wake
Copaxone Patent Suit: Is Teva Really Sure It Wants To Win The Case?
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel